Source: European Medicines Agency (EU) Revision Year: 2026 Publisher: ImmunityBio Ireland Limited, 6 th Floor, 2 Grand Canal Square, Dublin 2, Ireland, D02 A342
ANKTIVA 400 microgram concentrate for intravesical suspension.
| Pharmaceutical Form |
|---|
|
Concentrate for intravesical suspension. Nogapendekin alfa inbakicept is a clear to slightly opalescent, colourless to slightly yellow solution, pH 7.4. |
One vial (0.4 mL) contains 400 micrograms nogapendekin alfa inbakicept.
Nogapendekin alfa inbakicept is a complex consisting of two nogapendekin alfa bound to inbakicept, produced in Chinese hamster ovary (CHO-K1) cell line by recombinant technology.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Nogapendekin alfa inbakicept is an IL-15 receptor agonist. Binding of nogapendekin alfa inbakicept to its receptor results in proliferation and activation of NK, CD4+, CD8+, and memory T cells without proliferation of immuno-suppressive Treg cells. |
| List of Excipients |
|---|
|
Disodium phosphate |
0.4 mL solution in a glass vial with a serum stopper (chlorobutyl elastomer with a Flurotec B2-40 coating) and an aluminium alloy seal containing a yellow plastic polypropylene flip-off cap.
Pack size: 1 single-dose vial.
ImmunityBio Ireland Limited, 6th Floor, 2 Grand Canal Square, Dublin 2, Ireland, D02 A342
EU/1/25/2002/001
| Drug | Countries | |
|---|---|---|
| ANKTIVA | United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.